Calendar
Calendar of Events
July 2008
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031
Sponsor Links
Contact GoingtoMeet.com

Name
E-Mail
Message
Enter the code below:
If you can't read the image textto load another one.

Fast Facts

CancerNano 2008

Jun 01, 2008 - Jun 05, 2008
Hynes Convention Center Boston, Massachusetts United States
 

Highlights

Nanotechnology has the potential to have a revolutionary impact on cancer diagnosis and therapy. It is universally accepted that early detection of cancer is essential even before anatomic anomalies are visible. A major challenge in cancer diagnosis in the 21st century is to be able to determine the exact relationship between cancer biomarkers and the clinical pathology, as well as, to be able to non-invasively detect tumors at an early stage for maximum therapeutic benefit. For breast cancer, for instance, the goal of molecular imaging is to be able to accurately diagnose when the tumor mass has approximately 100-1000 cells, as opposed to the current techniques like mammography, which require more than a million cells for accurate clinical diagnosis.

In cancer therapy, targeting and localized delivery are the key challenges. To wage an effective war against cancer, we have to have the ability to selectively attack the cancer cells, while saving the normal tissue from excessive burdens of drug toxicity. However, because many anticancer drugs are designed to simply kill cancer cells, often in a semi-specific fashion, the distribution of anticancer drugs in healthy organs or tissues is especially undesirable due to the potential for severe side effects. Consequently, systemic application of these drugs often causes severe side effects in other tissues (e.g. bone marrow suppression, cardiomyopathy, neurotoxicity), which greatly limits the maximal allowable dose of the drug. In addition, rapid elimination and widespread distribution into non-targeted organs and tissues requires the administration of a drug in large quantities, which is often not economical and sometimes complicated due to non-specific toxicity. This vicious cycle of large doses and the concurrent toxicity is a major limitation of current cancer therapy. In many instances, it has been observed that the patient succumbs to the ill effects of the drug toxicity far earlier than the tumor burden.

This symposium will address the potential ways in which nanotechnology can address these challenges. Distinguished speakers will summarize the current state of the art and future barriers. Contributions are also solicited in the following topics.

Event Profiles

Sponsors: National Cancer Institute. National Institute of Health
Speakers: Mark N. Milton (Vice President of Nonclinical Development, Tempo Pharmaceuticals), Jack A. Roth (The University of Texas M. D. Anderson Cancer Center)

Contact Details

Contact person: Sarah Wenning
Email address:
Event website: http://www.nsti.org/Nanotech2008/symposia/Cancer_Diagnostics_Imaging_Treatment.html
Phone: (925) 901-4959
Fax: (925) 886-8461

See review

Contact Organizer

Contact Organizer
If you can't read the image text click here to reload.